Biomarker Data From Katherine: A Phase Iii Study Of Adjuvant Trastuzumab Emtansine (T-Dm1) Versus Trastuzumab (H) In Patients With Residual Invasive Disease After Neoadjuvant Therapy For Her2-Positive Breast Cancer.

Carsten Denkert,Chiara Lambertini,Peter A. Fasching,Katherine L. Pogue-Geile,Max S. Mano,Michael Untch,Norman Wolmark,Chiung-Sheng Huang,Sibylle Loibl,Eleftherios P. Mamounas,Gunter Von Minckwitz,Charles E. Geyer,Thomas Boulet,Chunyan Song,Gail Lewis Phillips,Malgorzata Nowicka,Sanne de Haas,Mark Basik

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 37|浏览58

暂无评分

摘要

502Background: The phase 3 KATHERINE study (NCT01772472) compared adjuvant T-DM1 versus H in patients with residual invasive breast cancer after neoadjuvant chemotherapy plus HER2-targeted therapy....

查看译文

关键词

adjuvant trastuzumab emtansine,breast cancer,neoadjuvant therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要